COMMUNIQUÉS West-GlobeNewswire

Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto
21/10/2026
Miv-cel reversed disability and achieved durable efficacy across all primary and secondary endpoints through one year, with nearly all patients remaining off chronic immunotherapies Deep B-cell depletion demonstrated [...]
INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027
21/10/2026
Final pre-MAA package submitted to MHRA on October 20, 2026 Full MAA submission targeted for early February 2027, under a revised strategy that could bring potential UK approval forward by approximately six weeks U.S. [...]
Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026
21/10/2026
VMS063 is a novel, potential first- and best-in-class monoclonal antibody investigational candidate discovered by Invivyd VMS063 demonstrated potent in vitro antiviral activity against contemporary measles virus [...]
What joint replacement involves, from the surgeon's credentials to the recovery plan
21/10/2026
Mount Pleasant, SC, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Novant Health Orthopedics & Sports Medicine Institute has published a patient guide on how to choose a joint replacement surgeon and hospital in the Charleston [...]
Sundance Biosciences Announces Presentation of Phase 1 Results for SUN-627, a Brain-Penetrant TYK2 Inhibitor for the Treatment of Multiple Sclerosis (MS)
21/10/2026
SUN-627 demonstrated favorable safety, tolerability, and pharmacokinetics for oral, once-daily dosing in healthy volunteers Achieved full central nervous system (CNS) penetration and >90% inhibition of TYK2 pathway [...]
Satellos to Participate in Upcoming Investor Conferences
21/10/2026
TORONTO, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage company developing potentially life-improving medicines to treat degenerative muscle diseases, today [...]
Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)
21/10/2026
Brepocitinib 45 mg once-daily achieved statistically significant benefit compared to placebo on the primary and all key secondary endpoints for each of CLARITY-1 and CLARITY-2, the two identical Phase 3 trials [...]
Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
21/10/2026
DURHAM, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT ) today announced that it will report its financial results for the second fiscal quarter ended September 30, 2026 on Monday, November 9, [...]
BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE
21/10/2026
—Expands BioCryst portfolio of targeted oral prophylactic therapy options to meet patients’ individual needs and preferences— —ORLADEYO is the first and only targeted oral prophylactic therapy with options for HAE [...]
Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
21/10/2026
A seasoned global people leader and organizational strategist, Ms. Aspesi will help scale Entrada’s people and organization for its next phase of growth BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, [...]
Vistin Pharma ASA: Invitation to Q3 2026 conference call
21/10/2026
Oslo, Norway, 21 October 2026 Vistin Pharma ASA (VISTN) will release its third quarter and YTD 2026 results on Thursday 29th of October 2026. Vistin Pharma will host a conference call for all shareholders and interested [...]
Promising Early Safety Data as Quell Therapeutics Advances QEL-005 – a Novel Engineered nTreg Therapy – to Second Dose Cohort in CHILL Phase 1/2 Trial in Difficult-to-Treat Rheumatoid Arthritis and Systemic Sclerosis
21/10/2026
Safe completion of the first dose cohort in which QEL-005 was well tolerated, with no dose-limiting toxicities (DLTs), no treatment-related adverse events of special interest (AESIs) and no serious adverse events (SAEs [...]
NRG Therapeutics Announces a PET Biodistribution Trial of Lead Clinical Asset NRG5051
21/10/2026
STEVENAGE, United Kingdom, Oct. 21, 2026 (GLOBE NEWSWIRE) -- NRG Therapeutics Ltd. (“NRG”), an innovative clinical stage neuroscience company targeting a novel mechanism to restore mitochondrial dysfunction in [...]
KFSH Forecasts Emergency Demand 24 Hours Ahead with AI as Time to See a Physician Falls 42%
21/10/2026
RIYADH, Saudi Arabia, Oct. 21, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) is using artificial intelligence to forecast Emergency Department demand 24 hours ahead, double its [...]
Bioxodes BIOX-101 Phase 2a data show statistically significant reduction in perihematomal edema growth in intracerebral hemorrhage
21/10/2026
First disclosure of new imaging analyses and one-year functional outcome were presented at the World Stroke Congress today Change in normalized hemorrhage volume was significantly lower with BIOX-101 versus standard of [...]
Avance Clinical to Meet European Biotechs at ESMO Congress 2026 and Appoints Wendy Hamon as Senior Vice President, Oncology Center of Excellence
21/10/2026
Executive Medical Director Dr George Peoples to discuss oncology programs from preclinical through Phase II in Madrid ADELAIDE, Australia, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Avance Clinical, a global full-service CRO [...]
Kylo Peptides Marks Record Month as Brand Searches Nearly Triple
21/10/2026
Sheridan, Wyoming, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides [ https://kylopeptides.com/ ], a research peptide supplier, recorded its highest month of brand search interest in September 2026. Estimated US searches [...]
ONWARD Medical Announces the Appointment of Fouad Azzam to its Board of Directors
21/10/2026
Fouad Azzam is a Partner with EQT Life Sciences, bringing extensive experience investing in and supporting fast-growing medical technology and life sciences companies EINDHOVEN, the Netherlands, Oct. 21, 2026 (GLOBE [...]
First Patient Treated in the C-FLASH-01 ConformalFLASH® Clinical Trial
21/10/2026
First Patient Treated in the C-FLASH-01 ConformalFLASH ® Clinical Trial Louvain-la-Neuve, Belgium, October 21, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum